发明名称 |
Orodispersible domperidone tablets |
摘要 |
The present invention relates to an orodispersible tablet comprised of, by weight: a maximum of 15% of a low-dose, therapeutically active substance; from 55% to 70% of mannitol of a particle size between 30 μm and 300 μm; at least 2% of maltodextrin; from 3.5% to 8% of croscarmellose sodium; from 10% to 20% of microcrystalline cellulose; from 0.5% to 1.5% of magnesium stearate; and from 1% to 5% of flavoring (s) and sweetener (s). |
申请公布号 |
US8852633(B2) |
申请公布日期 |
2014.10.07 |
申请号 |
US200712224945 |
申请日期 |
2007.03.14 |
申请人 |
Pierre Fabre Medicament |
发明人 |
Cordoliani Jean-François;Berthoumieu Didier |
分类号 |
A61K9/20;A61K31/445;A61K31/454;A61K9/00 |
主分类号 |
A61K9/20 |
代理机构 |
Birch, Stewart, Kolasch & Birch, LLP |
代理人 |
Birch, Stewart, Kolasch & Birch, LLP |
主权项 |
1. An orodispersible tablet comprised of, by weight:
a maximum of 15% of a low-dose, therapeutically active substance; from 55% to 70% of mannitol of a particle size between 30 μm and 300 μm; at least 2% of maltodextrin; from 3.5% to 8% of croscarmellose sodium; from 10% to 20% of microcrystalline cellulose; from 0.5% to 1.5% of magnesium stearate; and from 1% to 5% of flavoring (s) and sweetener (s);
wherein the tablet comprises a combination of an internal phase containing the therapeutic active substance and an initial portion of croscarmellose sodium, and an external phase containing a second portion of croscarmellose sodium; andwherein approximately half of the total quantity of sodium croscarmellose is distributed in the internal phase and approximately half is distributed in the external phase of the tablet. |
地址 |
Boulogne-Billancourt FR |